-
1دورية أكاديميةAflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
المؤلفون: Alsaedi NG, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, Al-Abdullah AA
المصدر: Clinical Ophthalmology, Vol Volume 15, Pp 2975-2980 (2021)
مصطلحات موضوعية: aflibercept, bevacizumab, persistent dme, ranibizumab, vegf switch, vascular endothelial growth factor, Ophthalmology, RE1-994
وصف الملف: electronic resource
-
2تقرير
المؤلفون: Alsaedi NG; King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.; King Abdullah Medical City, Makkah, Saudi Arabia., Alrubaie K; King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
المصدر: Case reports in ophthalmological medicine [Case Rep Ophthalmol Med] 2019 May 19; Vol. 2019, pp. 8392329. Date of Electronic Publication: 2019 May 19 (Print Publication: 2019).
نوع المنشور: Case Reports
بيانات الدورية: Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 101581018 Publication Model: eCollection Cited Medium: Print ISSN: 2090-6722 (Print) NLM ISO Abbreviation: Case Rep Ophthalmol Med Subsets: PubMed not MEDLINE